Liposomes conjugated with anti-CD8A antibodies represent a promising strategy to augment T cell-mediated immune responses, particularly in the context of melanoma immunotherapy. By targeting CD8A, these engineered liposomes can effectively recruit and activate cytotoxic T cells, leading to increased tumor infiltration and subsequent destruction of malignant cells. This innovative approach not only aims to improve the tumor microenvironment by reducing immunosuppression but also enhances the overall immune clearance capabilities against the tumor, potentially leading to better patient outcomes.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-369-VHH | Recombinant Anti-Mouse Cd8a VHH Single Domain Antibody | IHC, ICC, IP, ChiP, Neut | Llama VHH |
NABG-041 | Recombinant Anti-Human CD8A VHH Single Domain Antibody | IHC, FC, CA, FuncS | Llama VHH |
There are currently no Customer reviews or questions for VS-1024-FY169. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.